You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 5, May 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters to the Editor
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antiobsessional Effect of Risperidone Add-On Treatment in Serotonin Reuptake Inhibitor–Refractory Obsessive-Compulsive Disorder May Be Dose-Dependent

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In their recent article, McDougle et al1 concluded that patients with obsessive-compulsive disorder (OCD) refractory to serotonin reuptake inhibitor (SRI) monotherapy may respond to a mean ± SD low dose of risperidone (2.2 ± 0.7 mg) added to SRI treatment. However, the observed relationship between low doses of risperidone and its antiobsessional effect needs further evaluation.

Positron emission tomography studies have shown that risperidone, even at low doses (<=2 mg), exhibits a high occupancy of serotonin, (5-HT2) receptors (>=80%), while a moderate dose (2-6 mg) is required to induce 66% to 80% of dopamine type 2 (D2) occupancy.2 Dopamine type 2 antagonists such as pimozide and haloperidol seem to augment the efficacy of SRIs in refractory OCD with tics and schizotypal disorder,3-4 suggesting that dopamine D2 antagonism in combination with serotonin reuptake inhibition may enhance their therapeutic efficacy for OCD. Taking into account that D2 antagonism . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.